We are live on ! Find out more
CAPR icon

Capricor Therapeutics

19 hedge funds and large institutions have $2.29M invested in Capricor Therapeutics in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1919 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

0.12% less ownership

Funds ownership: 0.83%0.71% (-0.12%)

30% less capital invested

Capital invested by funds: $3.25M → $2.29M (-$964K)

Holders
19
Holders Change
Holders Change %
0%
% of All Funds
0.43%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
5
Reduced
5
Closed
1
Calls
Puts
Net Calls
Net Calls Change

CAPR Hedge Fund Activity: Q3 2018 in Review

19 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q3 2018, worth a combined $2.29M — down 30% from $3.25M a quarter earlier.

Fund positioning in CAPR was balanced in Q3 2018: 1 fund opened new positions, 1 closed out, 5 added to existing stakes and 5 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $19.6K. The largest seller was Brown Advisory, cutting an estimated $254K.

  • 19 institutional investors held Capricor Therapeutics (CAPR) as of Q3 2018, unchanged from Q2 2018.
  • Funds reported $2.29M of Capricor Therapeutics stock for Q3 2018, down 30% quarter-over-quarter.
  • 1 fund opened new Capricor Therapeutics positions in Q3 2018 and 1 closed out, a net change of 0 holders.
  • The largest Capricor Therapeutics buyer in Q3 2018 was Citadel Advisors, an estimated $19.6K added.
  • The largest Capricor Therapeutics seller in Q3 2018 was Brown Advisory, an estimated $254K sold.

Based on aggregated 13F filings for Q3 2018.